<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26679282</article-id><article-id pub-id-type="pmc">5324626</article-id><article-id pub-id-type="doi">10.1111/dom.12623</article-id><article-id pub-id-type="publisher-id">DOM12623</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Letters</subject></subj-group></article-categories><title-group><article-title>Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28&#x02009;weeks: a meta&#x02010;analysis of seven phase <styled-content style="fixed-case">III</styled-content> trials</article-title><alt-title alt-title-type="left-running-head">Seufert et al.</alt-title></title-group><contrib-group><contrib id="dom12623-cr-0001" contrib-type="author" corresp="yes"><name><surname>Seufert</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="dom12623-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12623-cr-0002" contrib-type="author"><name><surname>Bailey</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="dom12623-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12623-cr-0003" contrib-type="author"><name><surname>Barkholt Christensen</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="dom12623-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12623-cr-0004" contrib-type="author"><name><surname>Nauck</surname><given-names>M. A.</given-names></name><xref ref-type="aff" rid="dom12623-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="dom12623-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Division of Endocrinology and Diabetology Department of Internal Medicine II</named-content><institution>University Hospital of Freiburg</institution><named-content content-type="city">Freiburg</named-content><country country="DE">Germany</country></aff><aff id="dom12623-aff-0002"><label><sup>2</sup></label><institution>AMCR Institute Inc</institution><named-content content-type="city">Escondido</named-content><named-content content-type="country-part">CA</named-content><country country="US">USA</country></aff><aff id="dom12623-aff-0003"><label><sup>3</sup></label><institution>Novo Nordisk HQ</institution><named-content content-type="city">Bagsvaerd</named-content><country country="DK">Denmark</country></aff><aff id="dom12623-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Division of Diabetology Medical Department, St. Josef Hospital</named-content><institution>Ruhr&#x02010;University Bochum</institution><named-content content-type="city">Bochum</named-content><country country="DE">Germany</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence to</italic>: Jochen Seufert, Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany.<break/>
E&#x02010;mail: <email>jochen.seufert@uniklinik-freiburg.de</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2016</year></pub-date><volume>18</volume><issue>7</issue><issue-id pub-id-type="doi">10.1111/dom.2016.18.issue-7</issue-id><fpage>721</fpage><lpage>724</lpage><history><date date-type="received"><day>30</day><month>9</month><year>2015</year></date><date date-type="rev-recd"><day>08</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>14</day><month>12</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-18-721.pdf"/><abstract><p>This meta&#x02010;analysis of seven randomized, placebo&#x02010;controlled studies (total 3222 patients) evaluated whether type 2 diabetes (<styled-content style="fixed-case">T2D</styled-content>) duration affects the changes in blood glucose control and body weight that can be achieved with liraglutide and placebo. With liraglutide 1.2&#x02009;mg, shorter diabetes duration was associated with a significantly greater, but clinically non&#x02010;relevant, difference in glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>) reduction (p&#x02009;&#x0003c;&#x02009;0.05), i.e. a 0.18% (1.96&#x02009;mmol/mol) reduction in <styled-content style="fixed-case">HbA1c</styled-content> per 10&#x02009;years shorter diabetes duration. With liraglutide 1.8&#x02009;mg, shorter diabetes duration was associated with a small but statistically significant trend for greater fasting plasma glucose (<styled-content style="fixed-case">FPG</styled-content>) reduction (p&#x02009;&#x0003c;&#x02009;0.05), i.e. a 0.38&#x02009;mmol/l reduction in <styled-content style="fixed-case">FPG</styled-content> per 10&#x02009;years shorter diabetes duration. Neither the liraglutide 1.8&#x02009;mg nor placebo results showed a significant association between <styled-content style="fixed-case">HbA1c</styled-content> and diabetes duration and neither the liraglutide 1.2&#x02009;mg nor placebo results showed a significant association between <styled-content style="fixed-case">FPG</styled-content> and diabetes duration. Likewise, neither liraglutide nor placebo showed a significant association between change in weight and diabetes duration. These results suggest diabetes duration has a clinically negligible effect on achievable blood glucose control and weight outcomes with liraglutide and placebo in patients with <styled-content style="fixed-case">T2D</styled-content>.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12623-kwd-0001">HbA1c</kwd><kwd id="dom12623-kwd-0002">FPG</kwd><kwd id="dom12623-kwd-0003">weight</kwd><kwd id="dom12623-kwd-0004">diabetes duration</kwd></kwd-group><funding-group><award-group><funding-source>Novo Nordisk</funding-source></award-group></funding-group><counts><page-count count="4"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12623</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.7 mode:remove_FC converted:24.02.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="dom12623-note-0001a"><p>The copyright line for this article was changed on 16 February after original online publication.</p></fn></fn-group></notes></front><body><sec id="dom12623-sec-0001"><title>Introduction</title><p>Glucagon&#x02010;like peptide&#x02010;1 receptor agonists (GLP&#x02010;1RAs) are a mainstay of type 2 diabetes (T2D) therapy because of their ability to lower glucose with concomitant body weight reduction and low hypoglycaemia risk <xref rid="dom12623-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12623-bib-0002" ref-type="ref">2</xref>. As endogenous insulin secretion decreases with increased T2D duration, it might be expected that GLP&#x02010;1RAs would have a larger glucose&#x02010;lowering effect in the early stages of the disease. A recent trial raised the question that the use of the GLP&#x02010;1RA liraglutide, early in the T2D treatment paradigm, may have benefits for patients, such as preservation of &#x003b2;&#x02010;cell function <xref rid="dom12623-bib-0003" ref-type="ref">3</xref>. Furthermore, some studies have shown that glycated haemoglobin (HbA1c) reduction with liraglutide was significantly greater in patients with &#x02264;4&#x02009;years of diabetes duration, and the magnitude of HbA1c reduction was inversely related to diabetes duration <xref rid="dom12623-bib-0004" ref-type="ref">4</xref>, <xref rid="dom12623-bib-0005" ref-type="ref">5</xref>; however, data on the individual effect of diabetes duration <italic>per se</italic> on achievable blood glucose control and body weight reductions with GLP&#x02010;1RA, such as liraglutide, are limited.</p><p>The available data from the prospective Liraglutide Effect and Action in Diabetes (LEAD) studies, that measured efficacy and safety of liraglutide at doses up to 1.8&#x02009;mg, both as mono&#x02010; and combination therapies, together with a range of antidiabetic drugs, provide an opportunity to address this question. We therefore conducted a <italic>post hoc</italic>, pooled analysis to evaluate how T2D duration affected the observed changes in HbA1c, fasting plasma glucose (FPG) and body weight with liraglutide 1.8&#x02009;mg, liraglutide 1.2&#x02009;mg and placebo.</p></sec><sec id="dom12623-sec-0002"><title>Methods</title><p>Data from patients with T2D treated with liraglutide 1.2&#x02009;mg (n&#x02009;=&#x02009;1117), liraglutide 1.8&#x02009;mg (n&#x02009;=&#x02009;1581) or placebo (n&#x02009;=&#x02009;524) in seven phase III trials were included in this analysis <xref rid="dom12623-bib-0006" ref-type="ref">6</xref>, <xref rid="dom12623-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12623-bib-0008" ref-type="ref">8</xref>, <xref rid="dom12623-bib-0009" ref-type="ref">9</xref>, <xref rid="dom12623-bib-0010" ref-type="ref">10</xref>, <xref rid="dom12623-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12623-bib-0012" ref-type="ref">12</xref>. The 28&#x02010;week data from one study <xref rid="dom12623-bib-0008" ref-type="ref">8</xref> and 26&#x02010;week data from the six other trials were assessed <xref rid="dom12623-bib-0006" ref-type="ref">6</xref>, <xref rid="dom12623-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12623-bib-0009" ref-type="ref">9</xref>, <xref rid="dom12623-bib-0010" ref-type="ref">10</xref>, <xref rid="dom12623-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12623-bib-0012" ref-type="ref">12</xref>. The relationships of HbA1c, FPG or body weight (change from baseline) with diabetes duration were plotted using available data from the intention&#x02010;to&#x02010;treat population, using a last observation carried forward approach.</p><p>Data analyses were conducted by individual trial and pooled across trials. The slope for change in HbA1c or body weight versus diabetes duration was determined using a linear regression analysis (Figures S1&#x02013;S9, Supporting Information). The statistical analysis used the baseline endpoint value, diabetes duration and age as continuous covariates. Categorical covariates were previous treatment and country. Significance and non&#x02010;significance in discussing results refers to statistical significance, unless otherwise specified.</p></sec><sec id="dom12623-sec-0003"><title>Results</title><sec id="dom12623-sec-0004"><title>Patient Demographics</title><p>Patient demographics are described in Table S1, Supporting Information. Baseline T2D duration ranged from &#x0003c;1 to &#x0003e;40&#x02009;years, with a mean of &#x0223c;8&#x02009;years reported for the pooled groups (placebo, liraglutide 1.2&#x02009;mg and liraglutide 1.8&#x02009;mg).</p></sec><sec id="dom12623-sec-0005"><title>Change in <styled-content style="fixed-case">HbA1c</styled-content>, <styled-content style="fixed-case">FPG</styled-content> and Body Weight from Baseline</title><p>The 26&#x02010;/28&#x02010;week data showed clinically relevant reductions in HbA1c, FPG and body weight from baseline in patients treated with liraglutide 1.2 and 1.8&#x02009;mg compared with placebo (Tables S2 and S3, Supporting Information).</p></sec><sec id="dom12623-sec-0010"><title>Baseline data and trial design</title><p>The baseline data and design of each trial are described in Supplementary Tables&#x02009;4 and&#x02009;5, respectively.</p></sec><sec id="dom12623-sec-0006"><title>Effect of Diabetes Duration on Liraglutide Therapeutic Outcomes</title><p>With liraglutide 1.8&#x02009;mg, shorter diabetes duration was associated with a non&#x02010;significant trend for HbA1c reduction, i.e. a 0.07% (0.76&#x02009;mmol/mol) reduction in HbA1c per 10&#x02009;years shorter diabetes duration (Figure <xref rid="dom12623-fig-0001" ref-type="fig">1</xref>a and Table <xref rid="dom12623-tbl-0001" ref-type="table-wrap">1</xref>/Figure S2, Supporting Information). With liraglutide 1.2&#x02009;mg, shorter diabetes duration was associated with a small but significant trend of greater HbA1c reduction (p&#x02009;&#x0003c;&#x02009;0.05), equating to a 0.18% (1.96&#x02009;mmol/mol) reduction in HbA1c per 10&#x02009;years shorter diabetes duration (Figure <xref rid="dom12623-fig-0001" ref-type="fig">1</xref>a, Table <xref rid="dom12623-tbl-0001" ref-type="table-wrap">1</xref> and Figure S1, Supporting Information). No trends were observed in the corresponding placebo data (Figure <xref rid="dom12623-fig-0001" ref-type="fig">1</xref>a, Table <xref rid="dom12623-tbl-0001" ref-type="table-wrap">1</xref> and Figure S3, Supporting Information).</p><fig fig-type="Figure" xml:lang="en" id="dom12623-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(a) Effect of diabetes duration on change in glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>). (b) Effect of diabetes duration (<styled-content style="fixed-case">DD</styled-content>) on change in fasting plasma glucose (<styled-content style="fixed-case">FPG</styled-content>). (c) Effect of <styled-content style="fixed-case">DD</styled-content> on change in body weight. Data are modelled estimates with 95% confidence intervals. <styled-content style="fixed-case">DPP&#x02010;4i</styled-content>, dipeptidyl peptidase&#x02010;4 inhibitors. (a) and (c) with permission from: The effect of liraglutide on HbA1c and body weight is largely independent of baseline diabetes duration. Diabetes July 2013;62(Suppl 1):A217&#x02013;A364. Abstract 1033&#x02010;P, page A266. Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association.</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-18-721-g001"><alt-text>DOM-12623-FIG-0001-c</alt-text></graphic></fig><table-wrap id="dom12623-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Effect of diabetes duration on glycated haemoglobin, fasting plasma glucose and body weight (pooled estimates).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="left" valign="bottom" rowspan="1">Placebo</th><th colspan="3" align="left" valign="bottom" rowspan="1">Liraglutide 1.2&#x02009;mg</th><th colspan="3" align="left" valign="bottom" rowspan="1">Liraglutide 1.8&#x02009;mg</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Estimate</th><th align="left" valign="bottom" rowspan="1" colspan="1">Lower 95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">Upper 95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">Estimate</th><th align="left" valign="bottom" rowspan="1" colspan="1">Lower 95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">Upper 95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">Estimate</th><th align="left" valign="bottom" rowspan="1" colspan="1">Lower 95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">Upper 95% CI</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Body weight (kg per 10&#x02009;years DD)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.34</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.88</td><td align="left" valign="top" rowspan="1" colspan="1">0.20</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.18</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.24</td><td align="left" valign="top" rowspan="1" colspan="1">0.02</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.33</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">HbA1c, (% [mmol/mol] per 10&#x02009;years DD)</td><td align="left" valign="top" rowspan="1" colspan="1">0.03</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.15</td><td align="left" valign="top" rowspan="1" colspan="1">0.20</td><td align="left" valign="top" rowspan="1" colspan="1">0.18<xref ref-type="fn" rid="dom12623-note-0003">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.06</td><td align="left" valign="top" rowspan="1" colspan="1">0.30</td><td align="left" valign="top" rowspan="1" colspan="1">0.07</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.02</td><td align="left" valign="top" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">[0.28]</td><td align="left" valign="top" rowspan="1" colspan="1">[&#x02212;1.59]</td><td align="left" valign="top" rowspan="1" colspan="1">[2.14]</td><td align="left" valign="top" rowspan="1" colspan="1">[1.96]</td><td align="left" valign="top" rowspan="1" colspan="1">[0.71]</td><td align="left" valign="top" rowspan="1" colspan="1">[3.21]</td><td align="left" valign="top" rowspan="1" colspan="1">[0.76]</td><td align="left" valign="top" rowspan="1" colspan="1">[&#x02212;0.22]</td><td align="left" valign="top" rowspan="1" colspan="1">[1.74]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FPG, (mmol/l per 10&#x02009;years DD)</td><td align="left" valign="top" rowspan="1" colspan="1">0.27</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.14</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td><td align="left" valign="top" rowspan="1" colspan="1">0.29</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td><td align="left" valign="top" rowspan="1" colspan="1">0.38<xref ref-type="fn" rid="dom12623-note-0004">&#x02020;</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.19</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td></tr></tbody></table><table-wrap-foot><fn id="dom12623-note-0001"><p>Data are modelled estimates with 95% <styled-content style="fixed-case">CI</styled-content>, from intention&#x02010;to&#x02010;treat population, last observation carried forward.</p></fn><fn id="dom12623-note-0002"><p>
<styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">DD</styled-content>, diabetes duration; <styled-content style="fixed-case">FPG</styled-content>, fasting plasma glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin.</p></fn><fn id="dom12623-note-0003"><label>*</label><p>Shorter <styled-content style="fixed-case">DD</styled-content> was associated with a significantly (<styled-content style="fixed-case"><styled-content style="italic-in-any-context">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;0.05) greater <styled-content style="fixed-case">HbA1c</styled-content> reduction.</p></fn><fn id="dom12623-note-0004"><label>&#x02020;</label><p>Shorter <styled-content style="fixed-case">DD</styled-content> was associated with a significantly (<styled-content style="fixed-case"><styled-content style="italic-in-any-context">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;0.05) greater <styled-content style="fixed-case">FPG</styled-content> reduction.</p></fn></table-wrap-foot></table-wrap><p>With liraglutide 1.8&#x02009;mg, shorter diabetes duration was associated with a small but statistically significant trend for greater FPG reduction (p&#x02009;&#x0003c;&#x02009;0.05), equating to a 0.38&#x02009;mmol/l reduction in FPG per 10&#x02009;years shorter diabetes duration (Figure <xref rid="dom12623-fig-0001" ref-type="fig">1</xref>b, Figure S5, Supporting Information and Table <xref rid="dom12623-tbl-0001" ref-type="table-wrap">1</xref>). This was predominantly driven by results from two trials (LEAD 3 and LEAD 4), with liraglutide compared to glimepiride (both as monotherapy) in one trial, and used in combination with metformin and thiazolidinedione in the other <xref rid="dom12623-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12623-bib-0008" ref-type="ref">8</xref>. With liraglutide 1.2&#x02009;mg, there was no significant association between FPG and diabetes duration (Figure <xref rid="dom12623-fig-0001" ref-type="fig">1</xref>b, Table <xref rid="dom12623-tbl-0001" ref-type="table-wrap">1</xref> and Figure S4, Supporting Information). No significant trends for FPG reduction were observed in the corresponding placebo data (Figure <xref rid="dom12623-fig-0001" ref-type="fig">1</xref>b, Table <xref rid="dom12623-tbl-0001" ref-type="table-wrap">1</xref> and Figure S6, Supporting Information).</p><p>With liraglutide 1.8 and 1.2&#x02009;mg, no significant associations were observed between diabetes duration and change in body weight (Figure <xref rid="dom12623-fig-0001" ref-type="fig">1</xref>c, Table <xref rid="dom12623-tbl-0001" ref-type="table-wrap">1</xref> and Figures S8 and S7, Supporting Information, respectively), and no significant trend was seen with placebo (Figure <xref rid="dom12623-fig-0001" ref-type="fig">1</xref>c, Table <xref rid="dom12623-tbl-0001" ref-type="table-wrap">1</xref> and Figure S9, Supporting Information).</p></sec></sec><sec id="dom12623-sec-0007"><title>Discussion</title><p>This assessment shows that HbA1c, FPG and body weight responses observed during a clinical trial with liraglutide or placebo treatment are not significantly influenced by T2D duration. The population represented a large spectrum of diabetes duration and, therefore, may be considered to be representative of a continuum of different stages of disease progression, as is seen in clinical practice. Of note, however, the inclusion and exclusion criteria of the different trials may have selected the patients for suitability for liraglutide treatment, hence results may not be fully representative of the likely effect in the T2D population at large. There is also the additional influence of background therapy or other systematic study differences; moreover, not all liraglutide doses were studied in all trials.</p><p>It was found that, for liraglutide 1.2&#x02009;mg, shorter diabetes duration was associated with a significantly greater HbA1c reduction, although the effect was small and clinically non&#x02010;relevant. With liraglutide 1.8&#x02009;mg, a shorter duration was associated with significantly greater FPG reduction, but, again, the effect was small. If the effect was not spurious, statistically significantly greater reductions in HbA1c with shorter diabetes duration would have been expected at both doses, which was not the case. In addition, if the effect was not spurious, statistically significant greater reductions in both HbA1c and FPG efficacy at the same dose of liraglutide would have also been expected. Taking all these findings into consideration, our data indicate that these trends could be merely coincidental. In any case, they are of no clinical relevance for the estimation judgement of achievable outcomes with liraglutide treatment.</p><p>There was no significant association between change in body weight and diabetes duration, suggesting that the changes in body weight observed during a clinical trial with liraglutide or placebo treatment are completely independent of diabetes duration. Liraglutide influences glucose and weight reductions through different mechanisms; therefore, different trends with diabetes duration for HbA1c and FPG versus body weight could potentially be expected.</p><p>These study results suggest that the overall effects of liraglutide in patients with T2D may be less dependent on maintained endogenous insulin secretory capacity than previously thought in advanced states of diabetes, and that insulin&#x02010;independent actions of liraglutide [glucagonostatic effect and central nervous system effect (reduction of appetite)] may also contribute to the therapeutic outcome <xref rid="dom12623-bib-0002" ref-type="ref">2</xref>; however, it is worth noting that the vast majority of patients in the present study had a diabetes duration of &#x0003c;15&#x02009;years, and that insulin secretory capacity was not formally examined against changes in HbA1c and FPG.</p><p>In summary, our analysis suggests that diabetes duration <italic>per se</italic> has a clinically negligible effect on achievable HbA1c, FPG and weight outcomes with liraglutide 1.8, 1.2&#x02009;mg and placebo in patients with T2D. This suggests that treatment with the GLP&#x02010;1RA liraglutide may be effective in the treatment of T2D regardless of its duration.</p></sec><sec id="dom12623-sec-0009"><title>Conflict of Interest</title><p>J. S.
has attended advisory boards and/or speaker's bureaux for Takeda, Bayer, Novartis, Merck Sharp Dohme, Astra Zeneca, Bristol Myers Squibb, Novo Nordisk, Sanofi Aventis, Berlin Chemie, Eli Lilly, Boehringer Ingelheim, Merck, Roche, Ipsen, Pfizer, Janssen and Lifescan, and has received research support from Takeda, Novartis, Merck Sharp Dohme, Glaxo Smith Kline, Novo Nordisk, Sanofi Aventis, Ipsen, Pfizer, Janssen, Servier, Eli Lilly, Apitope, Intarcia and Roche. T. B. has provided research support to Abbott, ACON, Bayer, Bristol Myers Squibb, Dexcom, GlaxoSmithKline, Halozyme, Insulet, Janssen, Lexicon, Lifescan, Eli Lilly, Medtronic, Merck, Novo Nordisk, Orexigen and Sanofi, and has received consulting honoraria from Astra Zeneca, Bayer, BD, Eli Lilly, Medtronic, Novo Nordisk and Sanofi and speaking honoraria from Abbott, Insulet, Novo Nordisk and Sanofi. S.B.C is an employee of Novo Nordisk. M. A. N. has served on advisory boards for, received honoraria or consulting fees from, or received research funding from Amylin, AstraZeneca, Berlin&#x02010;Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Diartis Pharmaceuticals, Eli Lilly, GlaxoSmithKline, F. Hoffmann&#x02010;La Roche, Intarcia Therapeutics, Janssen, MannKind, Merck, MetaCure, Novartis, Novo Nordisk, Roche Pharmaceuticals, Sanofi, Takeda, Versartis and Wyeth Research.</p><p>J. S. contributed to the design, data analysis, interpretation, statistical analysis and writing the first manuscript draft. T. B. contributed to the data collection and interpretation. S. B. C. contributed to the interpretation and review. M. A. N. contributed to data analysis and interpretation. All authors reviewed and approved the final version of this article.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12623-supitem-0001"><caption><p>
<bold>Figure S1.</bold> Relationship between glycated haemoglobin and diabetes duration: liraglutide 1.2&#x02009;mg.</p><p>
<bold>Figure S2.</bold> Relationship between glycated haemoglobin and diabetes duration: liraglutide 1.8&#x02009;mg.</p><p>
<bold>Figure S3.</bold> Relationship between glycated haemoglobin and diabetes duration: placebo.</p><p>
<bold>Figure S4.</bold> Relationship between fasting plasma glucose and diabetes duration: liraglutide 1.2&#x02009;mg.</p><p>
<bold>Figure S5.</bold> Relationship between fasting plasma glucose and diabetes duration: liraglutide 1.8&#x02009;mg.</p><p>
<bold>Figure S6.</bold> Relationship between fasting plasma glucose and diabetes duration: placebo.</p><p>
<bold>Figure S7.</bold> Relationship between body weight and diabetes duration: liraglutide 1.2&#x02009;mg.</p><p>
<bold>Figure S8.</bold> Relationship between body weight and diabetes duration: liraglutide 1.8&#x02009;mg.</p><p>
<bold>Figure S9.</bold> Relationship between body weight and diabetes duration: placebo.</p><p>
<bold>Table S1.</bold> Baseline patient demographics.</p><p>
<bold>Table S2.</bold> Change in glycated haemoglobin, fasting plasma glucose and body weight from baseline (<styled-content style="fixed-case">LOCF</styled-content>).</p><p>
<bold>Table S3.</bold> Proportion of patients with glycated haemoglobin &#x0003c;7%.</p><p>
<bold>Table S4.</bold> Design of phase III studies included in meta&#x02010;analyses.</p><p>
<bold>Table S5.</bold> Baseline characteristics of liraglutide and placebo treatment groups from phase <styled-content style="fixed-case">III</styled-content> studies.</p></caption><media xlink:href="DOM-18-721-s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12623-sec-0008"><title>Acknowledgements</title><p>The authors thank Watermeadow Medical for assistance with preparation of this manuscript (funded by Novo Nordisk). This study was funded by Novo Nordisk.</p></ack><ref-list content-type="cited-references" id="dom12623-bibl-0001"><title>References</title><ref id="dom12623-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12623-cit-0001">
<string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name> et&#x02009;al. <article-title>Management of hyperglycemia in type 2 diabetes, 2015: a patient&#x02010;centred approach</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>: <fpage>140</fpage>&#x02013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">25538310</pub-id></mixed-citation></ref><ref id="dom12623-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12623-cit-0002">
<string-name>
<surname>Meier</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>GLP&#x02010;1 receptor agonists for individualized treatment of type 2 diabetes mellitus</article-title>. <source>Nat Rev Endocrinol</source>
<year>2012</year>; <volume>8</volume>: <fpage>728</fpage>&#x02013;<lpage>742</lpage>.<pub-id pub-id-type="pmid">22945360</pub-id></mixed-citation></ref><ref id="dom12623-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12623-cit-0003">
<string-name>
<surname>Retnakaran</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kramer</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Swaminathan</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Zinman</surname>
<given-names>B</given-names>
</string-name>. <article-title>Liraglutide and the preservation of pancreatic &#x003b2;&#x02010;cell function in early type 2 diabetes: the LIBRA trial</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>3270</fpage>&#x02013;<lpage>3278</lpage>.<pub-id pub-id-type="pmid">25249651</pub-id></mixed-citation></ref><ref id="dom12623-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12623-cit-0004">
<string-name>
<surname>Lapolla</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Frison</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Bettio</surname>
<given-names>M</given-names>
</string-name> et&#x02009;al. <article-title>Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real&#x02010;world setting in Italy</article-title>. <source>Clin Ther</source>
<year>2015</year>; <volume>37</volume>: <fpage>574</fpage>&#x02013;<lpage>584</lpage>.<pub-id pub-id-type="pmid">25626486</pub-id></mixed-citation></ref><ref id="dom12623-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12623-cit-0005">
<string-name>
<surname>Ponzani</surname>
<given-names>P</given-names>
</string-name>. <article-title>Long&#x02010;term effectiveness and safety of liraglutide in clinical practice</article-title>. <source>Minerva Endocrinol</source>
<year>2013</year>; <volume>38</volume>: <fpage>103</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">23435446</pub-id></mixed-citation></ref><ref id="dom12623-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12623-cit-0006">
<string-name>
<surname>Marre</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Br&#x000e4;ndle</surname>
<given-names>M</given-names>
</string-name> et&#x02009;al. <article-title>Liraglutide, a once&#x02010;daily human GLP&#x02010;1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD&#x02010;1 SU)</article-title>. <source>Diabet Med</source>
<year>2009</year>; <volume>26</volume>: <fpage>268</fpage>&#x02013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">19317822</pub-id></mixed-citation></ref><ref id="dom12623-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12623-cit-0007">
<string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Frid</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hermansen</surname>
<given-names>K</given-names>
</string-name> et&#x02009;al. <article-title>Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)&#x02010;2 study</article-title>. <source>Diabetes Care</source>
<year>2009</year>; <volume>32</volume>: <fpage>84</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">18931095</pub-id></mixed-citation></ref><ref id="dom12623-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12623-cit-0008">
<string-name>
<surname>Garber</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ratner</surname>
<given-names>R</given-names>
</string-name> et&#x02009;al. <article-title>Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD&#x02010;3 Mono): a randomised, 52&#x02010;week, phase III, double&#x02010;blind, parallel&#x02010;treatment trial</article-title>. <source>Lancet</source>
<year>2009</year>; <volume>373</volume>: <fpage>473</fpage>&#x02013;<lpage>481</lpage>.<pub-id pub-id-type="pmid">18819705</pub-id></mixed-citation></ref><ref id="dom12623-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12623-cit-0009">
<string-name>
<surname>Zinman</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gerich</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name> et&#x02009;al. <article-title>Efficacy and safety of the human glucagon&#x02010;like peptide&#x02010;1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD&#x02010;4 Met&#x02009;+&#x02009;TZD)</article-title>. <source>Diabetes Care</source>
<year>2009</year>; <volume>32</volume>: <fpage>1224</fpage>&#x02013;<lpage>1230</lpage>.<pub-id pub-id-type="pmid">19289857</pub-id></mixed-citation></ref><ref id="dom12623-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12623-cit-0010">
<string-name>
<surname>Russell&#x02010;Jones</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Vaag</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schmitz</surname>
<given-names>O</given-names>
</string-name> et&#x02009;al. <article-title>Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD&#x02010;5 met&#x02009;+&#x02009;SU): a randomised controlled trial</article-title>. <source>Diabetologia</source>
<year>2009</year>; <volume>52</volume>: <fpage>2046</fpage>&#x02013;<lpage>2055</lpage>.<pub-id pub-id-type="pmid">19688338</pub-id></mixed-citation></ref><ref id="dom12623-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12623-cit-0011">
<string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sesti</surname>
<given-names>G</given-names>
</string-name> et&#x02009;al. <article-title>Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26&#x02010;week randomised, parallel&#x02010;group, multinational, open&#x02010;label trial (LEAD&#x02010;6)</article-title>. <source>Lancet</source>
<year>2009</year>; <volume>374</volume>: <fpage>39</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">19515413</pub-id></mixed-citation></ref><ref id="dom12623-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12623-cit-0012">
<string-name>
<surname>Pratley</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>T</given-names>
</string-name> et&#x02009;al. <article-title>Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26&#x02010;week, randomised, parallel&#x02010;group, open&#x02010;label trial</article-title>. <source>Lancet</source>
<year>2010</year>; <volume>375</volume>: <fpage>1447</fpage>&#x02013;<lpage>1456</lpage>.<pub-id pub-id-type="pmid">20417856</pub-id></mixed-citation></ref></ref-list></back></article>